Samsara Therapeutics has announced the company’s autophagy-inducing candidate SAM001, the first agent of its class to enter clinical trials.

Gyros Protein Technologies AB has announced the introduction of Gyrolab® Generic Cyno Anti-Drug Antibodies Kit Reagents, for the detection of circulating immune complexes of human IgG with cyno anti-human IgG.

Personalis, Inc. has announced it has partnered with the Academic Breast Cancer Consortium and Criterium to carry out a prospective clinical trial to evaluate the clinical performance of the NeXT Personal® test.

An analysis of NHS prescriptions data has revealed the huge potential for pharmacogenomics to reduce ineffective prescribing and adverse effects, which could save millions of pounds for the NHS.

Avacta Group plc announces the opening of the first two clinical investigator sites for the phase 1 clinical trial of AVA6000 under its US Investigational New Drug Application.

Cantargia has announced it will host an R&D Day focusing on new clinical results and biomarker data for its lead asset, the IL1RAP-binding antibody nadunolimab, in pancreatic cancer patients.

MIP Discovery has announced the launch of its first drugs of abuse products which are able to recognize norfentanyl, the main urinary metabolite of fentanyl.

CureSearch for Children’s Cancer has announced that it will fund a Phase I clinical trial to bring new therapies to pediatric brain cancer patients, including those with limited or no treatment options.

EpicentRx, Inc. has announced that the FDA has granted Fast Track Designation to RRx-001 for the prevention/attenuation of severe oral mucositis in chemotherapy and radiation-treated head & neck cancer patients.

Cardiff Oncology, Inc. has announced that the first patient was dosed last month with its investigational drug onvansertib in its Phase II ONSEMBLE trial.